platinum based chemotherapy and nephrotoxicity epidemiology forecast

DelveInsight’s “Platinum-based Chemotherapy and Nephrotoxicity Epidemiology Forecast - 2034” report delivers an in-depth understanding of the Platinum-based Chemotherapy and Nephrotoxicity, historical and forecasted epidemiology as well as the Platinum-based Chemotherapy and Nephrotoxicity trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2021-2034

Platinum-based Chemotherapy and Nephrotoxicity Understanding

DelveInsight’s Platinum-based Chemotherapy and Nephrotoxicity epidemiology report give a thorough understanding of Platinum-based Chemotherapy and Nephrotoxicity. Chemotherapy is one of the most common cancer treatments, and it involves taking medications designed to destroy cancer cells. Many chemotherapy drugs are used to treat cancer, and one of the most frequently used categories is Platinum-based Chemotherapy drugs.

The platinum-based drugs cisplatin, carboplatin, and oxaliplatin are regularly prescribed to treat cancer. While they are effective, their use is limited by their severe, dose-limiting side effects. In particular, cisplatin is nephrotoxic and can cause acute kidney injury and chronic kidney disease. Stress responses, including autophagy, cell-cycle arrest, senescence, apoptosis, programmed necrosis, and inflammation, have key roles in the pathogenesis of cisplatin nephrotoxicity.

Cisplatin nephrotoxicity can present in several ways. However, the most serious and one of the more common presentations is acute kidney injury (AKI). Symptoms include hypomagnesemia, distal renal tubular acidosis, hyperuricemia, transient proteinuria, erythropoietin deficiency, and others. Evaluation of nephrotoxicity through blood tests includes the measurements of blood urea nitrogen (BUN), the concentration of serum creatinine, glomerular filtration rate, and creatinine clearance. However, these assessments of nephrotoxicity are only possible when a majority of kidney function is damaged.

Risk factors for predicting cisplatin-induced AKI include old age, females, smoking, hypoalbuminemia, hypokalemia, hypomagnesemia, a high body surface area, the frequency of cisplatin treatment, the combined use of cisplatin and paclitaxel, advanced cancer, the total dose of cisplatin administered, cardiovascular disease, and diabetes mellitus.

The mainstay approach to prevent cisplatin-induced nephrotoxicity is administering intravenous (IV) hydration with isotonic saline to increase renal blood flow and decrease the half-life of cisplatin and urinary cisplatin concentration. Many other agents have been studied, such as mannitol, N-acetyl cysteine, and furosemide. However, no agents have been established. Despite developing novel treatments, the present pharmacological landscape has some drawbacks. Amifostine is the only approved drug for the treatment of nephrotoxicity in ovarian cancer patients, and several pharmacological options are used off-label. Amifostine has been thought to be particularly relevant in patients with a high risk for renal toxicity, such as elderly patients.

Continued in the report…

Platinum-based Chemotherapy and Nephrotoxicity Epidemiology

The epidemiology section provides insights into the historical and current Platinum-based Chemotherapy and Nephrotoxicity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides a historical as well as forecasted Platinum-based Chemotherapy and Nephrotoxicity epidemiology scenario in the 7MM covering the United States, EU4 and the UK, and Japan from 2021 to 2034.

• In 2022, the total incident cases of cancer using platinum-based chemotherapy in the 7MM were approximately 2,675,600, and these cases are anticipated to increase during the study period, i.e., 2021-2034.
• The disease epidemiology covered in the report provides historical as well as forecasted Platinum-based Chemotherapy and Nephrotoxicity epidemiology [segmented as Total Incident Cases of Cancer using Platinum-based Chemotherapy, Stage-wise Incident Cases of Cancer, Line-wise Chemo-treated Cases, Platinum Therapy Treated Cases, Platinum-based Chemotherapy use by Cancers, and Total Platinum-induced Nephrotoxicity Cases] in the 7MM covering the United States, EU4 and the UK, and Japan from 2021 to 2034.

Country-wise Platinum-based Chemotherapy and Nephrotoxicity Epidemiology

The epidemiology segment also provides the Platinum-based Chemotherapy and Nephrotoxicity epidemiology data and findings across the United States, EU4 and the UK, and Japan.

• According to DelveInsight, in 2022, the total incident cases of cancer using platinum-based chemotherapy were approximately 970,900 in the United States, which is expected to grow during the study period, i.e., 2021-2034.
• Among EU4 and the UK, Germany had the highest number of cancer incident cases using platinum-based chemotherapy, with approximately 309,732 in 2022, expected to grow during the study period, i.e., 2021-2034.
• In 2022, the total incident cases of cancer using platinum-based chemotherapy were approximately 556,785 in Japan, which is expected to grow during the study period, i.e., 2021-2034.

KOL Views

To keep up with the current Platinum-based Chemotherapy and Nephrotoxicity patient pool and forecasted trend, we take KOLs and SMEs’ opinions working in the Platinum-based Chemotherapy and Nephrotoxicity domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report

• The report covers a descriptive overview of Platinum-based Chemotherapy and Nephrotoxicity, explaining their causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 and the UK, and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Platinum-based Chemotherapy and Nephrotoxicity.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM, Total Incident Cases of Cancer using Platinum-based Chemotherapy, Stage-wise Incident Cases of Cancer, Line-wise Chemo-treated Cases, Platinum Therapy Treated Cases, Platinum-based Chemotherapy use by Cancers, and Total Platinum-induced Nephrotoxicity Cases in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan from 2021 to 2034.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Platinum-based Chemotherapy and Nephrotoxicity R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Platinum-based Chemotherapy and Nephrotoxicity.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Platinum-based Chemotherapy and Nephrotoxicity Report Key Strengths

• 11 years Forecast
• 7MM Coverage
• Platinum-based Chemotherapy and Nephrotoxicity Epidemiology Segmentation

Key Questions

Epidemiology Insights

• What are the disease risk, burdens, and regional/ethnic differences between Platinum-based Chemotherapy and Nephrotoxicity?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 and the UK, and Japan?
• What are the historical Platinum-based Chemotherapy and Nephrotoxicity patient pools in seven major markets covering the United States, EU4 and the UK, and Japan?
• What would be the forecasted patient pool of Platinum-based Chemotherapy and Nephrotoxicity in seven major markets covering the United States, EU4 and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population regarding Platinum-based Chemotherapy and Nephrotoxicity?
• Out of all 7MM countries, which country would have the highest incident population of Platinum-based Chemotherapy and Nephrotoxicity during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

Reasons to buy

• The report will help develop business strategies by understanding trends shaping and driving the Platinum-based Chemotherapy and Nephrotoxicity disease market.
• To understand the future market competition in the Platinum-based Chemotherapy and Nephrotoxicity disease market.
• Organize sales and marketing efforts by identifying the best opportunities for Platinum-based Chemotherapy and Nephrotoxicity in the United States, EU4 (Germany, Spain, Italy, France) and the UK, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Platinum-based Chemotherapy and Nephrotoxicity disease market.
• To understand the future market competition in the Platinum-based Chemotherapy and Nephrotoxicity disease market.